Krista L Click here . Lentine, M.D., Tag A. Schnitzler, Ph.D., Huiling Xiao, M.S., Georges Saab, M.D., Paolo R. Salvalaggio, M.D., Ph.D., David Axelrod, M.D., Connie L. Davis, M.D., Kevin C. Abbott, M.D., M.P.H., and Daniel C. Brennan, M.D.: Racial Variation in Medical Outcomes among Living Kidney Donors Living kidney transplantation is considered to offer patients with end-stage renal disease the best chance of dialysis-free survival.1 In 2006, approximately 27,000 transplantations from registered living kidney donors had been performed worldwide,2 and living donors supplied nearly 40 percent of kidney transplants in the United States.3 Most evidence regarding the safety of living kidney donation for donors derives from single-center studies with limited statistical power and few nonwhite donors.4 In a recently available research, investigators at the University of Minnesota achieved high ascertainment of long-term patient and renal survival and reported no adverse effects of living kidney donation on life time or risk of end-stage renal disease, as compared with study data from the overall U.S.
The apparent discrepancy between the modes of inheritance of reduced LDL cholesterol and triglyceride levels and reduced HDL cholesterol levels also argues for distinct mechanisms of action on different lipoproteins. We discovered that carriers of ANGPTL3 non-sense mutations had decreased rates of VLDL apolipoprotein B production and elevated fractional catabolic rates for LDL apolipoprotein B. This shows that ANGPTL3 functions in the liver to regulate hepatocellular lipoprotein secretion and clearance directly, that is distinct from the function of the proteins in the inhibition of lipoprotein lipase and endothelial lipase in the bloodstream.